Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,338,073
  • Shares Outstanding, K 69,764
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,340 K
  • 60-Month Beta 2.94
  • Price/Sales 10.84
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.36
  • Number of Estimates 3
  • High Estimate 0.41
  • Low Estimate 0.28
  • Prior Year -0.87
  • Growth Rate Est. (year over year) +141.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.50 +6.40%
on 10/22/19
23.91 -22.12%
on 09/25/19
-3.12 (-14.35%)
since 09/20/19
3-Month
16.16 +15.22%
on 07/30/19
23.91 -22.12%
on 09/25/19
+1.56 (+9.14%)
since 07/22/19
52-Week
8.32 +123.80%
on 01/04/19
23.91 -22.12%
on 09/25/19
+6.53 (+54.01%)
since 10/22/18

Most Recent Stories

More News
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or "the Company", Nasdaq: CHRS), today announced that effective October 17, 2019, the compensation committee of the Company's board of directors granted options to...

CHRS : 18.62 (-2.92%)
Amag Pharmaceuti is Among the Companies in the Biotechnology Industry with the Best Relative Performance (AMAG , CHRS , KPTI , EXAS , EXEL )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AMAG : 11.70 (+1.92%)
CHRS : 18.62 (-2.92%)
KPTI : 11.37 (+2.06%)
Coherus BioSciences to Report Third Quarter Financial Results on November 6th

Coherus BioSciences, Inc. ("Coherus" or "the Company", Nasdaq: CHRS), today announced that its third quarter 2019 financial results will be released after market close on Wednesday, November 6, 2019. Starting...

CHRS : 18.62 (-2.92%)
Coherus Bioscien Set to Possibly Rebound After Yesterday's Selloff of 5.29%

Coherus Bioscien (NASDAQ:CHRS) traded in a range yesterday that spanned from a low of $19.47 to a high of $20.64. Yesterday, the shares fell 5.3%, which took the trading range below the 3-day low of...

CHRS : 18.62 (-2.92%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Sarepta Therapeu (SRPT , NTRA , CHRS , BLUE , PTCT )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CHRS : 18.62 (-2.92%)
NTRA : 37.56 (-5.77%)
SRPT : 85.55 (-1.24%)
Look for Shares of Coherus Bioscien to Potentially Pullback after Yesterday's 4.38% Rise

Coherus Bioscien (NASDAQ:CHRS) traded in a range yesterday that spanned from a low of $20.70 to a high of $22.00. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high...

CHRS : 18.62 (-2.92%)
Shares of Aimmune Therapeu Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (AIMT , CHRS , HRTX , KPTI , CARA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AIMT : 25.44 (-1.32%)
CHRS : 18.62 (-2.92%)
HRTX : 18.58 (-2.39%)
First Week of CHRS May 2020 Options Trading

Investors in Coherus BioSciences Inc saw new options begin trading this week, for the May 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the...

CHRS : 18.62 (-2.92%)
Adamas Pharmaceu has the Best Relative Performance in the Biotechnology Industry (ADMS , AMAG , CHRS , XNCR , INCY )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ADMS : 4.04 (+1.00%)
AMAG : 11.70 (+1.92%)
CHRS : 18.62 (-2.92%)
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective September 19, 2019, the compensation committee of the company's board of directors granted 7 new employees options to purchase an...

CHRS : 18.62 (-2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade CHRS with:

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

2nd Resistance Point 20.06
1st Resistance Point 19.34
Last Price 18.62
1st Support Level 17.70
2nd Support Level 16.78

See More

52-Week High 23.91
Last Price 18.62
Fibonacci 61.8% 17.95
Fibonacci 50% 16.11
Fibonacci 38.2% 14.28
52-Week Low 8.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar